SequelSEC

OS Therapies Inc OSTX

Pharmaceutical Preparations · CIK 0001795091 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
Unavailable
Fiscal year ended 2025-12-31
Operating income
-$28.71M
Fiscal year ended 2025-12-31
Free cash flow
Unavailable
Fiscal year ended 2025-12-31

OS Therapies Inc (OSTX) reported net income of -$28.75M for the fiscal year ended 2025-12-31. This page shows 3 annual periods of income statement, balance sheet and cash flow figures normalized from OS Therapies Inc’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

OS Therapies Inc income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-31
RevenueUnavailableUnavailableUnavailable
Cost of revenueUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailable
Operating income-$28.71M-$6.81M-$4.34M
Net income-$28.75M-$8.88M-$7.79M
Research & development$16.36M$2.84M$3.22M
Weighted-average diluted sharesshares 29.25Mshares 6.95MUnavailable
Pretax incomeUnavailableUnavailableUnavailable
Income tax expenseUnavailableUnavailableUnavailable
Diluted EPS$-0.98$-1.28$-1.46
Selling, general & administrativeUnavailableUnavailableUnavailable
General & administrative$12.34M$3.97M$1.13M
Selling & marketingUnavailableUnavailableUnavailable

Balance

OS Therapies Inc balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-31
Cash & equivalentsUnavailableUnavailableUnavailable
Total assets$6.84M$5.54M$798.08K
Current assets$332.91K$5.53M$790.03K
Total liabilities$11.86M$4.73M$24.81M
Current liabilities$11.76M$4.63M$24.71M
Total equity incl. NCI-$6.10M-$3.27M-$24.02M
Temporary (mezzanine) equity$1.07M$4.08MUnavailable
InventoryUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailableUnavailable
GoodwillUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailable
Accounts payable$9.94M$1.66M$2.72M

Cash flow

OS Therapies Inc cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-31
Operating cash flow-$14.24M-$7.28M-$3.01M
Capital expendituresUnavailableUnavailableUnavailable
Investing cash flow-$466.42KUnavailable$1.14K
Financing cash flow$9.44M$12.78M$2.87M
Net change in cashUnavailableUnavailableUnavailable
Stock-based compensation$4.27M$268.30KUnavailable
Common dividends paidUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailable
Depreciation & amortization$363.08K$2.78KUnavailable

Derived

OS Therapies Inc derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-31
Free cash flowUnavailableUnavailableUnavailable
Gross marginUnavailableUnavailableUnavailable
Operating marginUnavailableUnavailableUnavailable
FCF marginUnavailableUnavailableUnavailable
SBC / revenueUnavailableUnavailableUnavailable
Current ratio0.03x1.20x0.03x
Revenue YoY growthUnavailableUnavailableUnavailable
Net marginUnavailableUnavailableUnavailable
R&D / revenueUnavailableUnavailableUnavailable
CapEx / revenueUnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open OSTX in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-14View SEC filing
10-Q · Filed 2026-05-18View SEC filing
10-K · Filed 2026-03-31View SEC filing
10-Q · Filed 2025-11-14View SEC filing
10-Q · Filed 2025-08-18View SEC filing
10-Q · Filed 2025-05-15View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.